Optometrists limitations on prescribing and administering drugs provisions modifications
Summary
SF1144 amends Minnesota’s optometry statute to modify the limits on what optometrists may prescribe or administer in the course of treating diseases and conditions of the eye and related structures. The bill keeps optometry within the existing framework of diagnosing visual conditions, prescribing lenses and vision therapy, and using legend drugs for eye care, but it updates the list of prohibited drug uses and routes of administration.
Under the bill, optometrists would still be barred from administering legend drugs intravenously, intramuscularly, or by injection, except in limited situations such as anaphylaxis or certain eye-specific injections. The bill also continues to prohibit invasive surgery, including laser surgery, and restricts Schedule II and III oral legend drugs and oral steroids. It further limits oral antivirals to 10 days, steroids to 14 days without physician consultation, and oral carbonic anhydrase inhibitors to 7 days.
Impact
The bill would amend Minnesota Statutes section 148.56, subdivision 1, which defines the practice of optometry and sets the scope of drug prescribing and administration authority. Its practical effect is to refine the scope of optometric prescribing authority while preserving major restrictions on injections, surgery, and certain higher-risk oral medications. The affected parties are licensed optometrists, patients receiving eye care, and, indirectly, physicians and other health professionals involved in consultation or referral for more complex treatment.
Sentiment
Based on the bill text and available legislative context, the measure appears to be a technical professional-scope update rather than a broadly controversial policy change. The authorship suggests support from legislators interested in clarifying or adjusting optometric practice authority, and there is no recorded committee testimony or vote history in the provided materials indicating organized opposition or strong public controversy. Overall sentiment appears neutral to mildly supportive, with the bill framed as a targeted modification to existing health-occupation rules.
Contention
The main points of contention likely center on the boundaries of optometric practice, especially whether optometrists should have broader authority to prescribe or administer drugs and how much physician oversight should remain in place. The bill preserves significant limits on injections, surgery, and certain oral medications, which suggests concern about patient safety and the distinction between optometry and medicine. Any disagreement would likely come from stakeholders balancing expanded access to eye care against worries about scope creep, training, and referral safeguards.